{"id":455454,"date":"2021-03-11T01:57:54","date_gmt":"2021-03-11T06:57:54","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=455454"},"modified":"2021-03-11T01:57:54","modified_gmt":"2021-03-11T06:57:54","slug":"kintor-pharmaceutical-announces-results-from-investigator-initiated-brazil-trial-demonstrating-92-reduction-in-mortality-in-hospitalized-covid-19-patients","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/kintor-pharmaceutical-announces-results-from-investigator-initiated-brazil-trial-demonstrating-92-reduction-in-mortality-in-hospitalized-covid-19-patients\/","title":{"rendered":"Kintor Pharmaceutical Announces Results from Investigator-Initiated Brazil Trial Demonstrating 92% Reduction in Mortality in Hospitalized COVID-19 Patients"},"content":{"rendered":"
\n

PR Newswire<\/p>\n<\/p><\/div>\n

\n

SUZHOU,\u00a0China, March 11, 2021<\/span> \/PRNewswire\/ — Kintor Pharmaceutical Limited (HKEX: 9939), a clinical-stage biotechnology\u00a0company developing\u00a0small molecule and biological\u00a0therapeutics, announced today top-line results from its investigator-initiated\u00a0Brazil trial evaluating the efficacy of Proxalutamide relative to standard of\u00a0care as assessed by the COVID-19 ordinal scale.\u00a0In the clinical trial, Proxalutamide met the primary endpoint at day 14, demonstrating a reduction of 4.01 in WHO COVID-19 ordinal scale from a baseline\u00a0of 5.663 to 1.653 in the\u00a0Proxalutamide\u00a0arm versus a reduction of 0.25 from a baseline of 5.618 to\u00a05.368 in the\u00a0control\u00a0arm with a p value <0.0001. Proxalutamide also demonstrated a reduction in mortality risk by 92% (3.7% vs 47.6%) and shortened median hospital length stayby 9 days (median hospital stay of 5 days vs 14 days).<\/p>\n

The investigator-initiated trial (NCT04728802), conducted by Dr. Andy Goren<\/span> and Dr.Fl\u00e1vio Adsuara Cadegiani, is a placebo-controlled, double-blinded randomized parallel assignment and multi-center study. The trial has two cohorts (men and women) and two arms (Proxalutamide and control). It enrolled 588 patients who met the eligibility criteria within 48 hours of admission to hospital.\u00a0<\/p>\n

In the Proxalutamide arm, patients were orally administered Proxalutamide 300mg once daily (QD) for 14 days. In the control arm, patients were orally administered placebo once daily (QD) for 14 days. Each arm also received standard of care as determined by the principal investigator at the site. The primary endpoint of the trial is the treatment efficacy of Proxalutamide relative to control, as assessed by the WHO COVID-19 ordinal scale on day 14.<\/p>\n

The preliminary analysis conducted on March 9, 2021<\/span> was based on 294 patients (56.8% male) inthe Proxalutamide arm and 296 patients (57.8% male) in the control arm. According to the results on day 14, the mortality in Proxalutamide arm was 11(3.7%), compared to 141 (47.6%) in control arm, demonstrating a reduced mortality risk of 92%. The number of new mechanical ventilation (MV) and\/ordeath in Proxalutamide arm was 13 (4.4%), compared to 156 (52.7%) in control arm, reducing mortality risk by 92%; and median hospital length stay (days) in Proxalutamide arm was 5, while it was 14 in control arm, which means\u00a0Proxalutamide shortened hospital stay by 9 days.<\/p>\n

\n\n\n\n\n\n\n\n
\n \n <\/td>\n\n

\n
\n Proxalutamide
arm<\/b>
\n <\/span>\n <\/p>\n

\n \uff08n=294\uff09<\/span>\n <\/p>\n<\/td>\n

\n

\n
\n Control arm<\/b>
\n <\/span>\n <\/p>\n

\n \uff08n=296\uff09<\/span>\n <\/p>\n<\/td>\n<\/tr>\n

\n \n <\/td>\n\n

\n Cases<\/span>\n <\/p>\n<\/td>\n

\n

\n Percentage<\/span>\n <\/p>\n<\/td>\n

\n

\n Cases<\/span>\n <\/p>\n<\/td>\n

\n

\n Percentage<\/span>\n <\/p>\n<\/td>\n<\/tr>\n

\n

\n Mortality<\/span>\n <\/p>\n

\n Day 14<\/span>\n <\/p>\n<\/td>\n

\n

\n 11<\/span>\n <\/p>\n<\/td>\n

\n

\n 3.7%<\/span>\n <\/p>\n<\/td>\n

\n

\n 141<\/span>\n <\/p>\n<\/td>\n

\n

\n 47.6%[1]<\/sup><\/span>\n <\/p>\n<\/td>\n<\/tr>\n

\n

\n Hospital Length
Stay (Days)<\/span>\n <\/p>\n<\/td>\n

\n

\n 5<\/span>\n <\/p>\n<\/td>\n

\n

\n 14<\/span>\n <\/p>\n<\/td>\n<\/tr>\n

\n

\n New mechanical
ventilation (MV)
and\/or Death<\/span>\n <\/p>\n

\n Day 14<\/span>\n <\/p>\n<\/td>\n

\n

\n 13<\/span>\n <\/p>\n<\/td>\n

\n

\n 4.4%<\/span>\n <\/p>\n<\/td>\n

\n

\n 156<\/span>\n <\/p>\n<\/td>\n

\n

\n 52.7%<\/span>\n <\/p>\n<\/td>\n<\/tr>\n

\n

\n Discharged from
hospital<\/span>\n <\/p>\n

\n Day 14<\/span>\n <\/p>\n<\/td>\n

\n

\n 262<\/span>\n <\/p>\n<\/td>\n

\n

\n 89.1%<\/span>\n <\/p>\n<\/td>\n

\n

\n 97<\/span>\n <\/p>\n<\/td>\n

\n

\n 32.8%<\/span>\n <\/p>\n<\/td>\n<\/tr>\n<\/table><\/div>\n

Dr. Tong Youzhi, Founder, Chairman and Chief Executive Officer of Kintor Pharmaceutical, commented, “This trial for treatment of hospitalized COVID-19 patients was conducted in 12 sites in the Brazilian state of Amazonas, where the pandemic has been devastating. Most of the newly test-positive patients in Amazonas have been infected by the new P.1 variant, which is more contagious and has led to a higher mortality rate. We are delighted to see that Proxalutamide could significantly reduce the mortality rate, shorten the length of hospital stay, reduce the number of new mechanical ventilations (MV), and increase the percentage of discharge from hospital, thus alleviating shortages of public health resources in Amazonas. Based on thepositive results of this phase 3 trial, the treatment of COVID-19 outpatients, hospitalized patients\u00a0(including those admitted to Intensive Care Units), we expect Proxalutamide could become an important\u00a0tool in the global fight againstCOVID-19. We at Kintor Pharmaceuticals thank Dr. Andy Goren<\/span> , Dr.Fl\u00e1vio Adsuara Cadegiani and the Samel Group for their continued efforts.”<\/p>\n

\n About Proxalutamide(GT-0918)<\/b>\n <\/p>\n

Proxalutamideis a nonsteroidal antiandrogen \u2013 specifically, a selective high-affinity silentantagonist of the androgen receptor \u2013 which is under development for thepotential treatment of COVID-19, prostate cancer, and breast cancer.<\/p>\n

\n About Kintor Pharmaceuticals<\/b>\n <\/p>\n

Kintor Pharmaceuticals is developing and commercializing a robust pipeline of smallmolecule and biological drugs for androgen-receptor-related disease areas with unmet medical needs, including COVID-19, prostate, breast and liver cancer, alopecia and acne. For more information, visit\u00a0www.kintor.com.cn<\/a>. <\/p>\n

\n [1]<\/sup>\u00a0According to\u00a0The Lancet, a 50% (n = 13,496) mortality rate was reported for in-hospital mortality in North Brazil<\/span> (Amazonas).\u00a0Accessed 10 March 2021<\/span>. https:\/\/www.thelancet.com\/journals\/lanres\/article\/PIIS2213-2600(20)30560-9\/fulltext<\/a> \u00a0 <\/p>\n

\n

\n Contact Information<\/b>\n <\/p>\n

\n IR Team:
<\/b>
\n IR@kintor.com.cn<\/a>\n <\/p>\n

\n PR Team:
<\/b>
\n PR@kintor.com.cn<\/a>\n <\/p>\n

\n

\n MessagingLAB
<\/b>
\n Karl Schmieder<\/span>
\n
\n karl@messaginglab.com<\/a>\n <\/p>\n

\n Solebury Trout
<\/b>Bob Ai
Bai@soleburytrout.com<\/a><\/p>\n

\n

\n

\n \"Cision\" View original content:http:\/\/www.prnewswire.com\/news-releases\/kintor-pharmaceutical-announces-results-from-investigator-initiated-brazil-trial-demonstrating-92-reduction-in-mortality-in-hospitalized-covid-19-patients-301245257.html<\/a><\/p>\n

SOURCE Kintor Pharmaceuticals<\/p>\n<\/p><\/div>\n

\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

PR Newswire SUZHOU,\u00a0China, March 11, 2021 \/PRNewswire\/ — Kintor Pharmaceutical Limited (HKEX: 9939), a clinical-stage biotechnology\u00a0company developing\u00a0small molecule and biological\u00a0therapeutics, announced today top-line results from its investigator-initiated\u00a0Brazil trial evaluating the efficacy of Proxalutamide relative to standard of\u00a0care as assessed by the COVID-19 ordinal scale.\u00a0In the clinical trial, Proxalutamide met the primary endpoint at day 14, demonstrating a reduction of 4.01 in WHO COVID-19 ordinal scale from a baseline\u00a0of 5.663 to 1.653 in the\u00a0Proxalutamide\u00a0arm versus a reduction of 0.25 from a baseline of 5.618 to\u00a05.368 in the\u00a0control\u00a0arm with a p value <0.0001. Proxalutamide also demonstrated a reduction in mortality risk by 92% (3.7% vs 47.6%) and shortened median hospital length stayby 9 days (median hospital stay of 5 days vs 14 … <\/p>\n

Continue reading “Kintor Pharmaceutical Announces Results from Investigator-Initiated Brazil Trial Demonstrating 92% Reduction in Mortality in Hospitalized COVID-19 Patients”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-455454","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nKintor Pharmaceutical Announces Results from Investigator-Initiated Brazil Trial Demonstrating 92% Reduction in Mortality in Hospitalized COVID-19 Patients - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/kintor-pharmaceutical-announces-results-from-investigator-initiated-brazil-trial-demonstrating-92-reduction-in-mortality-in-hospitalized-covid-19-patients\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Kintor Pharmaceutical Announces Results from Investigator-Initiated Brazil Trial Demonstrating 92% Reduction in Mortality in Hospitalized COVID-19 Patients - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PR Newswire SUZHOU,\u00a0China, March 11, 2021 \/PRNewswire\/ — Kintor Pharmaceutical Limited (HKEX: 9939), a clinical-stage biotechnology\u00a0company developing\u00a0small molecule and biological\u00a0therapeutics, announced today top-line results from its investigator-initiated\u00a0Brazil trial evaluating the efficacy of Proxalutamide relative to standard of\u00a0care as assessed by the COVID-19 ordinal scale.\u00a0In the clinical trial, Proxalutamide met the primary endpoint at day 14, demonstrating a reduction of 4.01 in WHO COVID-19 ordinal scale from a baseline\u00a0of 5.663 to 1.653 in the\u00a0Proxalutamide\u00a0arm versus a reduction of 0.25 from a baseline of 5.618 to\u00a05.368 in the\u00a0control\u00a0arm with a p value <0.0001. Proxalutamide also demonstrated a reduction in mortality risk by 92% (3.7% vs 47.6%) and shortened median hospital length stayby 9 days (median hospital stay of 5 days vs 14 … Continue reading "Kintor Pharmaceutical Announces Results from Investigator-Initiated Brazil Trial Demonstrating 92% Reduction in Mortality in Hospitalized COVID-19 Patients"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/kintor-pharmaceutical-announces-results-from-investigator-initiated-brazil-trial-demonstrating-92-reduction-in-mortality-in-hospitalized-covid-19-patients\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-03-11T06:57:54+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/c212.net\/c\/img\/favicon.png?sn=CN06553&sd=2021-03-11\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kintor-pharmaceutical-announces-results-from-investigator-initiated-brazil-trial-demonstrating-92-reduction-in-mortality-in-hospitalized-covid-19-patients\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kintor-pharmaceutical-announces-results-from-investigator-initiated-brazil-trial-demonstrating-92-reduction-in-mortality-in-hospitalized-covid-19-patients\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Kintor Pharmaceutical Announces Results from Investigator-Initiated Brazil Trial Demonstrating 92% Reduction in Mortality in Hospitalized COVID-19 Patients\",\"datePublished\":\"2021-03-11T06:57:54+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kintor-pharmaceutical-announces-results-from-investigator-initiated-brazil-trial-demonstrating-92-reduction-in-mortality-in-hospitalized-covid-19-patients\\\/\"},\"wordCount\":685,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kintor-pharmaceutical-announces-results-from-investigator-initiated-brazil-trial-demonstrating-92-reduction-in-mortality-in-hospitalized-covid-19-patients\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/c212.net\\\/c\\\/img\\\/favicon.png?sn=CN06553&sd=2021-03-11\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kintor-pharmaceutical-announces-results-from-investigator-initiated-brazil-trial-demonstrating-92-reduction-in-mortality-in-hospitalized-covid-19-patients\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kintor-pharmaceutical-announces-results-from-investigator-initiated-brazil-trial-demonstrating-92-reduction-in-mortality-in-hospitalized-covid-19-patients\\\/\",\"name\":\"Kintor Pharmaceutical Announces Results from Investigator-Initiated Brazil Trial Demonstrating 92% Reduction in Mortality in Hospitalized COVID-19 Patients - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kintor-pharmaceutical-announces-results-from-investigator-initiated-brazil-trial-demonstrating-92-reduction-in-mortality-in-hospitalized-covid-19-patients\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kintor-pharmaceutical-announces-results-from-investigator-initiated-brazil-trial-demonstrating-92-reduction-in-mortality-in-hospitalized-covid-19-patients\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/c212.net\\\/c\\\/img\\\/favicon.png?sn=CN06553&sd=2021-03-11\",\"datePublished\":\"2021-03-11T06:57:54+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kintor-pharmaceutical-announces-results-from-investigator-initiated-brazil-trial-demonstrating-92-reduction-in-mortality-in-hospitalized-covid-19-patients\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kintor-pharmaceutical-announces-results-from-investigator-initiated-brazil-trial-demonstrating-92-reduction-in-mortality-in-hospitalized-covid-19-patients\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kintor-pharmaceutical-announces-results-from-investigator-initiated-brazil-trial-demonstrating-92-reduction-in-mortality-in-hospitalized-covid-19-patients\\\/#primaryimage\",\"url\":\"https:\\\/\\\/c212.net\\\/c\\\/img\\\/favicon.png?sn=CN06553&sd=2021-03-11\",\"contentUrl\":\"https:\\\/\\\/c212.net\\\/c\\\/img\\\/favicon.png?sn=CN06553&sd=2021-03-11\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kintor-pharmaceutical-announces-results-from-investigator-initiated-brazil-trial-demonstrating-92-reduction-in-mortality-in-hospitalized-covid-19-patients\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Kintor Pharmaceutical Announces Results from Investigator-Initiated Brazil Trial Demonstrating 92% Reduction in Mortality in Hospitalized COVID-19 Patients\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Kintor Pharmaceutical Announces Results from Investigator-Initiated Brazil Trial Demonstrating 92% Reduction in Mortality in Hospitalized COVID-19 Patients - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/kintor-pharmaceutical-announces-results-from-investigator-initiated-brazil-trial-demonstrating-92-reduction-in-mortality-in-hospitalized-covid-19-patients\/","og_locale":"en_US","og_type":"article","og_title":"Kintor Pharmaceutical Announces Results from Investigator-Initiated Brazil Trial Demonstrating 92% Reduction in Mortality in Hospitalized COVID-19 Patients - Market Newsdesk","og_description":"PR Newswire SUZHOU,\u00a0China, March 11, 2021 \/PRNewswire\/ — Kintor Pharmaceutical Limited (HKEX: 9939), a clinical-stage biotechnology\u00a0company developing\u00a0small molecule and biological\u00a0therapeutics, announced today top-line results from its investigator-initiated\u00a0Brazil trial evaluating the efficacy of Proxalutamide relative to standard of\u00a0care as assessed by the COVID-19 ordinal scale.\u00a0In the clinical trial, Proxalutamide met the primary endpoint at day 14, demonstrating a reduction of 4.01 in WHO COVID-19 ordinal scale from a baseline\u00a0of 5.663 to 1.653 in the\u00a0Proxalutamide\u00a0arm versus a reduction of 0.25 from a baseline of 5.618 to\u00a05.368 in the\u00a0control\u00a0arm with a p value <0.0001. Proxalutamide also demonstrated a reduction in mortality risk by 92% (3.7% vs 47.6%) and shortened median hospital length stayby 9 days (median hospital stay of 5 days vs 14 … Continue reading \"Kintor Pharmaceutical Announces Results from Investigator-Initiated Brazil Trial Demonstrating 92% Reduction in Mortality in Hospitalized COVID-19 Patients\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/kintor-pharmaceutical-announces-results-from-investigator-initiated-brazil-trial-demonstrating-92-reduction-in-mortality-in-hospitalized-covid-19-patients\/","og_site_name":"Market Newsdesk","article_published_time":"2021-03-11T06:57:54+00:00","og_image":[{"url":"https:\/\/c212.net\/c\/img\/favicon.png?sn=CN06553&sd=2021-03-11","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kintor-pharmaceutical-announces-results-from-investigator-initiated-brazil-trial-demonstrating-92-reduction-in-mortality-in-hospitalized-covid-19-patients\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kintor-pharmaceutical-announces-results-from-investigator-initiated-brazil-trial-demonstrating-92-reduction-in-mortality-in-hospitalized-covid-19-patients\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Kintor Pharmaceutical Announces Results from Investigator-Initiated Brazil Trial Demonstrating 92% Reduction in Mortality in Hospitalized COVID-19 Patients","datePublished":"2021-03-11T06:57:54+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kintor-pharmaceutical-announces-results-from-investigator-initiated-brazil-trial-demonstrating-92-reduction-in-mortality-in-hospitalized-covid-19-patients\/"},"wordCount":685,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kintor-pharmaceutical-announces-results-from-investigator-initiated-brazil-trial-demonstrating-92-reduction-in-mortality-in-hospitalized-covid-19-patients\/#primaryimage"},"thumbnailUrl":"https:\/\/c212.net\/c\/img\/favicon.png?sn=CN06553&sd=2021-03-11","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kintor-pharmaceutical-announces-results-from-investigator-initiated-brazil-trial-demonstrating-92-reduction-in-mortality-in-hospitalized-covid-19-patients\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/kintor-pharmaceutical-announces-results-from-investigator-initiated-brazil-trial-demonstrating-92-reduction-in-mortality-in-hospitalized-covid-19-patients\/","name":"Kintor Pharmaceutical Announces Results from Investigator-Initiated Brazil Trial Demonstrating 92% Reduction in Mortality in Hospitalized COVID-19 Patients - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kintor-pharmaceutical-announces-results-from-investigator-initiated-brazil-trial-demonstrating-92-reduction-in-mortality-in-hospitalized-covid-19-patients\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kintor-pharmaceutical-announces-results-from-investigator-initiated-brazil-trial-demonstrating-92-reduction-in-mortality-in-hospitalized-covid-19-patients\/#primaryimage"},"thumbnailUrl":"https:\/\/c212.net\/c\/img\/favicon.png?sn=CN06553&sd=2021-03-11","datePublished":"2021-03-11T06:57:54+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kintor-pharmaceutical-announces-results-from-investigator-initiated-brazil-trial-demonstrating-92-reduction-in-mortality-in-hospitalized-covid-19-patients\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/kintor-pharmaceutical-announces-results-from-investigator-initiated-brazil-trial-demonstrating-92-reduction-in-mortality-in-hospitalized-covid-19-patients\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kintor-pharmaceutical-announces-results-from-investigator-initiated-brazil-trial-demonstrating-92-reduction-in-mortality-in-hospitalized-covid-19-patients\/#primaryimage","url":"https:\/\/c212.net\/c\/img\/favicon.png?sn=CN06553&sd=2021-03-11","contentUrl":"https:\/\/c212.net\/c\/img\/favicon.png?sn=CN06553&sd=2021-03-11"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kintor-pharmaceutical-announces-results-from-investigator-initiated-brazil-trial-demonstrating-92-reduction-in-mortality-in-hospitalized-covid-19-patients\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Kintor Pharmaceutical Announces Results from Investigator-Initiated Brazil Trial Demonstrating 92% Reduction in Mortality in Hospitalized COVID-19 Patients"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/455454","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=455454"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/455454\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=455454"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=455454"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=455454"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}